UnknownNot Applicable

Performance Evaluation of the Biological Diagnosis of HIT

France894 participantsStarted 2022-06-27

Plain-language summary

Heparin-induced thrombocytopenia (HIT) is a severe complication of heparin therapy with a non-negligible incidence (estimated at 2.6% of unfractionated heparin treatments and 0.2% of low molecular weight heparin treatments). It is generally secondary to the appearance of IgG antibodies directed against the platelet factor 4 (PF4) - heparin complex. These antibodies, once bound to this complex, are likely to activate platelets: the thrombotic risk generated can be potentially fatal.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria : * Adult patient (≥ 18 years of age) * Hospitalized at HUS between 01/01/2009 and 31/12/2019 * Specimen sent to the HUS Hematology Laboratory for biological diagnosis of HIT between 01/01/2009 and 31/12/2019 * Data collected by the CRPV and analyzed by the HIT multidisciplinary group in order to reach a consensus decision on the presence or absence of HIT * Patient does not object to the reuse of his medical data for scientific research purposes. Exclusion criteria: * Patient for whom no test has been performed at the HUS Hematology Laboratory * Patient for whom no data has been collected by the CRPV * Patient for whom the HIT group could not confirm or deny the presence of HIT

What they're measuring

Retrospective description of the biological diagnosis approach for heparin-induced thrombocytopenia (HIT) in the Hematology laboratory of the University Hospitals of Strasbourg

Timeframe: through study completion, an average of 1 month

Trial details

NCT IDNCT06180785

SponsorUniversity Hospital, Strasbourg, France

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-12

Contact for this trial

Agathe HERB, PharmD

33 3 88 12 75 53 agathe.herb@chru-strasbourg.fr